CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Levobupivacaine +1 moredrug
Likely dose
Levobupivacaine 3.75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03607227
NCT03607227Phase 4Completed

Does Continuous Popliteal Nerve Block Improve Pain Management for Patients Undergoing Major Maxilla or Mandible Resection With Microvascular Reconstruction Using a Free Fibula Graft

Region Skane·interventional·Posted Jul 31, 2018·Updated Apr 8, 2021

In Brief

A Phase 4 clinical trial evaluating Levobupivacaine and Saline Solution for Head and Neck Cancer and Pain, Musculoskeletal. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The aim of the study is to assess the effects of a continuous popliteal block on postoperative pain and recovery after major ear, nose and throat surgery with microvascular free flap reconstruction using a fibula graft.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedJul 31, 2018
Enrollment StartSep 1, 2018
Primary CompletionApr 6, 2021
Study CompletionApr 7, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.9 years ago

Interventions

Levobupivacainedrug

Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.

Saline Solutiondrug

Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.